Zeneca Limited

Other

Jeffrey Alan McKinney

Timothy W Davenport

Thomas Michael Bare

Charles D McLaren

Marc Jerome Chapdelaine

James Roy Empfield

Richard Bruce Sparks

Laura Enid Garcia-Davenport

Paul Francis Jackson

Paul F Jackson

The present invention relates to Ibogaine derivatives and related methods. It more specifically relates to deutero- and fluoro-derivatives of Ibogaine and related methods. In one aspect, the present invention provides a compound. The structure of the compound is shown as compoundin FIG.. In another aspect, the present invention provides a method of treating an addiction disorder. The method comprises administration of compound. In another aspect, the present invention provides a method of treating an anxiety-related disorder or impulse control disorder. The method comprises administration of compound

Ibogaine-related compounds and corresponding methods

The present invention relates to compounds, pharmaceutical compositions and methods of using compounds having the formula below

Pyridazino quinoline compounds

The invention relates to pyridazinoquinoline compounds of the formulas B and B&prime;

The present invention concerns compounds according to the following formula, ##STR1## wherein: R.sup.1 is (CH.sub.2).sub.n,L where n is an integer in the range 0 to 6, and L is a carbon-linked five-membered heteroaryl ring having an oxygen or sulfur heteroatom, R.sup.4 is hydrogen, halo or NO.sub.2, and pharmaceutical compositions and methods of using thereof in the treatment and/or prevention of neurological diseases or conditions.

Heteroaryl-substituted pyridazino quinoline compounds

Antagonists at the NMDA receptor complex which are benz�b!azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Substituted nitrogen heterocycles

Pyridazion quinoline compounds

Antagonists at the NMDA receptor complex which are benz[b]azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Antagonists at the NMDA receptor complex which are benz b!azepines having a hydroxy, alkoxy or amino substituent at the 3-position and a 4-position alkenyl, alkynyl, aryl or heteroaryl substituent for treatment of stroke and/or other neurodegenerative disorders.

Growing community of inventors

Palo Alto, CA, United States of America

Jeffrey Alan McKinney